GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Total Stockholders Equity

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Total Stockholders Equity : $-10.98 Mil (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Total Stockholders Equity?

Alseres Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2014 was $-10.98 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Alseres Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2014 was $-1,856.44. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Alseres Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2014 was -0.77.

Alseres Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Alseres Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals Total Stockholders Equity Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.51 -47.29 -30.25 -26.35 -10.27

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.89 -27.26 -10.27 -10.62 -10.98

Alseres Pharmaceuticals  (OTCPK:ALSE) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Alseres Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2014 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-10.979-0.401)/0.00613
=-1,856.44

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Alseres Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2014 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.119 + 8.297) / -10.979
=-0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alseres Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Total Stockholders Equity
Comparable Companies
NSPX OBMP BOM:506365 BOM:532041 ATRX PPCB WAR:PFM RSPI TSXV:MFS BOM:542765 HSTC CAPS ATMS AKAOQ BRTX TSXV:PBS BOM:532871 APOP TSXV:APC ONTX
Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Website
http://www.alseres.com
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines

From GuruFocus

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 05-15-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-14-2009